An Explorative Analysis of <i>ABCG2/TOP-1</i> mRNA Expression as a Biomarker Test for FOLFIRI Treatment in Stage III Colon Cancer Patients: Results from Retrospective Analyses of the PETACC-3 Trial.

Cancers (Basel) · 2020 · PMC7226226 · PMID 32326511

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

In another retrospective PETACC-3 study [ 7 ], we reported for low TOP1 expression a trend towards an association with short RFS and a borderline significant association with shorter OS in the irinotecan treated patients but not in the 5FUL treated patients [ 7 ].

also in 11,409 other papers

did not reach statistical significanceno p-value reported

When we included only MSS+MSI-L patients, the differences in RFS and OS between FOLFIRI and 5FUL patients and ABCG2/TOP1 status became more pronounced but still did not reach statistical significance, most probably due to the low number of included patients.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.